Nimustine

Nimustine

SCHEMBL23301409

Cc1ncc(CNC(=O)N(CCCl)N=O)c(N)n1.Cc1ncc(CNC(=O)N(CCCl)N=O)c(N)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BLM P54132 2/20 1.00
PMP22 Q01453 2/20 1.00
LMNA P02545 2/20 1.00
NFKB1 P19838 1/20 1.00
ALDH1A1 P00352 2/20 0.45
TSHR P16473 2/20 0.45
MEN1 O00255 1/20 0.45
ABCB11 O95342 1/20 0.45
GSR P00390 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 1/20 0.45
ADRA2A P08913 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP1A2 P05177 1/20 0.36
PDE4A P27815 1/20 0.35
ADRA1A P35348 1/20 0.35
TKT P29401 4/20 0.35
EGFR P00533 1/20 0.34
ERBB2 P04626 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nimustine SCHEMBL8414 1.00 BLM (1.00) BLMPMP22LMNANFKB1ALDH1A1
Nimustine SCHEMBL98303 0.99 BLM (0.98) BLMPMP22LMNANFKB1ALDH1A1
Nimustine SCHEMBL1649545 0.99 BLM (0.98) BLMPMP22LMNANFKB1ALDH1A1
Nimustine SCHEMBL124427 0.99 BLM (0.98) BLMPMP22LMNANFKB1ALDH1A1
Nimustine SCHEMBL1649348 0.98 BLM (0.96) BLMPMP22LMNANFKB1ALDH1A1
Nimustine SCHEMBL1580335 0.96 BLM (0.92) BLMPMP22LMNANFKB1ALDH1A1
Nimustine SCHEMBL5886061 0.89 BLM (0.80) BLMPMP22LMNANFKB1ALDH1A1
SCHEMBL25299723 0.88 LMNA (0.79) BLMPMP22LMNANFKB1TKT
SCHEMBL17524414 0.88 BLM (0.79) BLMPMP22LMNANFKB1ALDH1A1
SCHEMBL6541875 0.83 LMNA (0.71) BLMPMP22LMNANFKB1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021110085-A1 METHOD FOR ASSOCIATING WITH EXPRESSION LEVEL OF AKR1C3 ENZYME VIA CONTENT OF PROSTAGLANDIN, AND USE OF SCREENING FOR DRUG ADMINISTRATION 深圳艾欣达伟医药科技有限公司 2021-06-10 WO claimed
WO-2021083310-A1 ANTI-CANCER COMPOUNDS ACTING AS NON-PGP SUBSTRATE 深圳艾欣达伟医药科技有限公司 2021-05-06 WO claimed
WO-2021110085-A1 METHOD FOR ASSOCIATING WITH EXPRESSION LEVEL OF AKR1C3 ENZYME VIA CONTENT OF PROSTAGLANDIN, AND USE OF SCREENING FOR DRUG ADMINISTRATION 深圳艾欣达伟医药科技有限公司 2021-06-10 WO disclosed
WO-2021083310-A1 ANTI-CANCER COMPOUNDS ACTING AS NON-PGP SUBSTRATE 深圳艾欣达伟医药科技有限公司 2021-05-06 WO disclosed